<code id='98281F2756'></code><style id='98281F2756'></style>
    • <acronym id='98281F2756'></acronym>
      <center id='98281F2756'><center id='98281F2756'><tfoot id='98281F2756'></tfoot></center><abbr id='98281F2756'><dir id='98281F2756'><tfoot id='98281F2756'></tfoot><noframes id='98281F2756'>

    • <optgroup id='98281F2756'><strike id='98281F2756'><sup id='98281F2756'></sup></strike><code id='98281F2756'></code></optgroup>
        1. <b id='98281F2756'><label id='98281F2756'><select id='98281F2756'><dt id='98281F2756'><span id='98281F2756'></span></dt></select></label></b><u id='98281F2756'></u>
          <i id='98281F2756'><strike id='98281F2756'><tt id='98281F2756'><pre id='98281F2756'></pre></tt></strike></i>

          knowledge

          knowledge

          author:fashion    Page View:156
          John-Arne-Røttingen, a white man with short hair, smiles at the camera wearing blue suits — biotech coverage from STAT
          John-Arne Røttingen is the head of the Wellcome Trust, one of the world’s top private funders of biomedical research. Illustration: STAT; Source: Wellcome Trust

          LONDON — The key groups involved in addressing global health problems often include governments, foundations, and pharmaceutical companies.

          But to John-Arne Røttingen, the new head of the Wellcome Trust, one of the world’s top private funders of biomedical research, there’s another sector that should be getting involved — the tech industry.

          advertisement

          The Alphabets and Amazons of the world have been growing their health-related initiatives, but the industry is rarely mentioned when neglected public health issues are discussed, Røttingen argued.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          How one medical school became remarkably diverse
          How one medical school became remarkably diverse

          ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

          read more
          Gene therapy denied for Afghan refugee whose father aided U.S.
          Gene therapy denied for Afghan refugee whose father aided U.S.

          ThePashaichildren(fromleft):Abubakar,Mohammad,andSufyan.Illustration:STAT;PhotoCourtesyOnasweltering

          read more
          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more

          Allen Institute goes after foundational questions, CEO Costa says

          AllenInstituteCEORuiCostaCourtesyAllenInstituteMappingthebillionsofcellsthatmakeupthebrainisataskmam